Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: Catalyst Grant: Post Market Drug Safety and Effectiveness

University of British Columbia

$97,900.00

Multiple lines of evidence on the long term impacts of antipyschotic exposure on height, weight, BMI, and educational attainment developed using propensity score matched comparison groups and instrumental variables

EF 2011-12

Résumé
Antipsychotics are widely prescribed in Canada and the United States and there has been a dramatic increase in prescriptions of antipsychotics among children and adolescents in both countries. Our own work found a more than five-fold increase in antipsychotic prescriptions for males aged 6 to 18 and among females age 13 and older in British Columbia. In the US, Alexander et al. report an eight-fold increase in patient visits where a typical or atypical antipsychotic drug was reported between 1995 and 2005 among patients under the age of 18. And yet, Health Canada has not approved any antipsychotic medications for children. Although controlled trials have shown that second generation or atypical antipsychotics are less likely to have neurological side effects, serious adverse metabolic side effects including weight gain, diabetes, hyperlipidemia and hypertension have been found. On the other hand clinical studies have pointed to improved social functioning by patients receiving these treatments, and clinicians point to the potential benefits that would result if these drugs allowed children to stay in school. Assessing the current state of knowledge about these drugs, Dr. Jonathan Mink, a consult to the FDA's Pediatric Advisory Committee said, "There is serious concern that children may be at a higher risk for serious adverse effects and we just don't have sufficient data to answer that question." This study will provide key evidence on long-term risks and benefits of these drugs, information that is critically needed by doctors, patients and parents so that they can make informed assessments of the risks and benefits of these new and powerful drugs.
Programme
Catalyst Grant: Post Market Drug Safety and Effectiveness
Emplacement
British Columbia, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database

Tel que publié

Id
244083
Name
Maclure Malcolm
Region
British Columbia
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Human Development, Child and Youth Health
Theme2
Social / Cultural / Environmental / Population Health
Prcname2
Catalyst Grant: Post Market Drug Safety and Effectiveness
Projecttitle
Multiple lines of evidence on the long term impacts of antipyschotic exposure on height, weight, BMI, and educational attainment developed using propensity score matched comparison groups and instrumental variables
Programtype2
Operating Grants
Orgnameinp2
University of British Columbia
Cihramount2
$97,900
Cihrequipment2
$0
Programname2
Catalyst Grant: Post Market Drug Safety and Effectiveness
Keyworddelim
Administrative Data; Antipsychotic Medications; Child & Adolescent Psychiatry; Drug Effectiveness; Drug Safety; High-Dimensional Propensity Scores; Metabolic Effects; Pharmacoepidemiology
Abstract
Antipsychotics are widely prescribed in Canada and the United States and there has been a dramatic increase in prescriptions of antipsychotics among children and adolescents in both countries. Our own work found a more than five-fold increase in antipsychotic prescriptions for males aged 6 to 18 and among females age 13 and older in British Columbia. In the US, Alexander et al. report an eight-fold increase in patient visits where a typical or atypical antipsychotic drug was reported between 1995 and 2005 among patients under the age of 18. And yet, Health Canada has not approved any antipsychotic medications for children. Although controlled trials have shown that second generation or atypical antipsychotics are less likely to have neurological side effects, serious adverse metabolic side effects including weight gain, diabetes, hyperlipidemia and hypertension have been found. On the other hand clinical studies have pointed to improved social functioning by patients receiving these treatments, and clinicians point to the potential benefits that would result if these drugs allowed children to stay in school. Assessing the current state of knowledge about these drugs, Dr. Jonathan Mink, a consult to the FDA's Pediatric Advisory Committee said, "There is serious concern that children may be at a higher risk for serious adverse effects and we just don't have sufficient data to answer that question." This study will provide key evidence on long-term risks and benefits of these drugs, information that is critically needed by doctors, patients and parents so that they can make informed assessments of the risks and benefits of these new and powerful drugs.
Competitiondate
201110
Approvedterm2
1 yr 0 mth
Pinamesdelim
Maclure, Malcolm; Panagiotopoulos, Constadina
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $97,900~ $0~
University of British Columbia - $97,900 Grant (2011-… | Canada Spends